Search

Phase I Trials

Current

Code Title
ID93 A Phase Ib Randomized, Double-blind, Placebo-controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the ID93+GLA-SE vaccine in BCG-vaccinated Healthy Adults.

Completed

Code Title
MVA85 A-Protocol 008 A Phase I study evaluating the safety and immunogenicity of a new TB vaccine, MVA85A, in healthy volunteers with no evidence of infection with Mycobacterium tuberculosis.
MVA85 A-Protocol 011 A Phase I study evaluating the safety and immunogenicity of a new TB vaccine, MVA85A, in asymptomatic volunteers who are infected with either Mycobacterium tuberculosis (M.tb.), Human Immunodeficiency Virus (HIV) or both.
Aeras 402 Vaccine Protocol 003 Phase I Double-Blind, Randomized, Placebo Controlled, Dose Escalation Study to Evaluate Safety and Immunogenicity of AERAS-402 in HIV-negative, BCG- Vaccinated Males and Females in South Africa Without Evidence of Tuberculosis.
Aeras 402 Protocol 018 Phase I Double-blind Randomized Controlled Dose Escalation Study to Evaluate Safety and Immunogenicity of AERAS-402 in BCG vaccinated, HIV-negative Infants at Least 6 Months of Age without Evidence of Tuberculosis.
Aeras 404 Protocol 011 A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS‑404 When Administered as a Single Adjuvant Amount with Different Antigen Amounts in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection.